Long-Term Outcomes following Alemtuzumab Induction in Lung Transplantation
DOI:
https://doi.org/10.1532/HSF98.2013160Abstract
Objectives: Alemtuzumab is a commonly used induction agent for solid-organ transplantation. Its use in lung transplantation with reduced immunosuppressive regimens, however, has yet to be well characterized.
Methods: From November 2006 to March 2008, 20 consecutive lung transplantation patients received alemtuzumab induction with a reduced maintenance immunosuppression regimen. Twenty consecutive case-controls who underwent transplantation between 2005 and 2006 were treated with a standard immunosuppression regimen without induction. Outcome variables were patient survival, acute rejection, infection, and bronchiolitis obliterans syndrome.
Results: Mean follow-up time was 1400 days in the alemtuzumab group and 1210 days in the control group. Double lung transplantation was performed in 21 patients (12 in the alemtuzumab group and 9 in the control group). There was no difference in survival between the alemtuzumab (n = 10) and control (n = 10) groups. There was also not a significant difference in time-adjusted death based on Kaplan-Meier analysis. The mean number of any grade of rejection event per patient was not significantly different (alemtuzumab 2.3 ± 2.7 vs. control 3.2 ± 2.35; P = .22). There was a trend toward the reduced incidence of infection requiring intravenous antibiotics per patient (alemtuzumab 2.4 vs. control 3.8; P = .08). The incidence of bronchiolitis obliterans syndrome was similar in both groups (alemtuzumab 55% vs. control 70%; P = .25).
Conclusions: Alemtuzumab induction with reduced immunosuppression offers a comparable 5-year survival and rejection rate compared to standard-dose immunosuppression regimen.
References
Ailawadi G, Smith PW, Oka T, et al. 2008. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. J Thorac Cardiovasc Surg 135:594-602.nAllan JS. 2004. Immunosuppression for lung transplantation. Semin Thorac Cardiovasc Surg 16:333-41.nCai J, Teraski PI. 2010. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 90:1511-5.nChristie JD, Edwards LB, Kucheryavaya AY, et al. 2011. The Registry of the International Society for Heart and Lung Transplantation: Twentyeighth Adult Lung and Heart-Lung Transplant Report—2011. J Heart Lung Transplant 30:1104-22.nEstenne M, Maurer JR, Boehler A, et al. 2002. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21:297-310.nHachem RR, Edwards LB, Yusen RD, Chakinala MM, Patterson GA, Trulock EP. 2008. The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. Clin Transplant 22:603-8.nHanaway MJ, Woodle ES, Mulgaonkar S, et al. 2011. Alemtuzumab induction in renal transplantation. N Engl J Med 364:1909-19.nMcCurry KR, Iacono A, Zeevi A, et al. 2005. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 130:528-37.nShyu S, Dew MA, Pilewski JM, et al. 2011. Five-year outcomes with alemtuzumab induction after lung transplantation. J Heart Lung Transplant 30:743-54.nZeevi A, Husain S, Spichty KJ, et al. 2007. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 7:471-5.n
